Matinas BioPharma

(NYSEMKT) MTNB

Current Price$0.65

Market Cap$4.16M

Since IPO (2014)-99%

5 Year-98%

1 Year-28%

1 Month-8%

Matinas BioPharma Financials at a Glance

Market Cap

$4.16M

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.23M

EPS (TTM)

-$2.02

P/E Ratio

-0.32

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$0.65

Volume

885

Open

$0.66

Price

$0.65

Volume

885

Open

$0.66

Previous Close

$0.65

Daily Range

$0.66 - $0.66

52-Week Range

$0.48 - $3.09

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$0.65

Volume

885

Open

$0.66

Previous Close

$0.65

Daily Range

$0.66 - $0.66

52-Week Range

$0.48 - $3.09

Estimated Earnings Date

Aug 13, 2026

MTNB News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Matinas BioPharma

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Jerome D. Jabbour

Website

www.matinasbiopharma.com

Headquarters

Bedminster, NJ 07921, US

MTNB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-204.27%

Return on Capital

-112.55%

Return on Assets

-191.15%

Earnings Yield

-3.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.16M

Shares Outstanding

6.41M

Volume

885

Avg. Volume

149.95K

Financials (TTM)

Gross Profit

-$227.00K

Operating Income

-$6.95M

EBITDA

-$9.72M

Operating Cash Flow

-$6.61M

Capital Expenditure

$0.00

Free Cash Flow

-$6.61M

Cash & ST Invst.

$2.45M

Total Debt

$1.19M

Matinas BioPharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$74.00K

+12.9%

Gross Margin

0.00%

N/A

Market Cap

$4.16M

N/A

Market Cap/Employee

$1.39M

N/A

Employees

N/A

Net Income

-$1.92M

-16.0%

EBITDA

-$1.85M

-12.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$2.45M

-64.6%

Total Debt

$1.19M

-56.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$469.00K

-75.6%

Short Term Debt

$720.00K

-9.3%

Return on Assets

-1.91%

N/A

Return on Invested Capital

-1.85%

N/A

Free Cash Flow

-$1.60M

+20.2%

Operating Cash Flow

-$1.60M

+20.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KTTAPasithea Therapeutics Corp.

KTTAPasithea Therapeutics Corp.$0.55-1.80%

ADXNAddex Therapeutics Ltd

ADXNAddex Therapeutics Ltd$6.05+0.83%

CDIOCardio Diagnostics Holdings, Inc.

CDIOCardio Diagnostics Holdings, Inc.$2.11+3.94%

ACXPAcurx Pharmaceuticals, Inc.

ACXPAcurx Pharmaceuticals, Inc.$1.52+3.40%

HCWBHCW Biologics Inc.

HCWBHCW Biologics Inc.$1.15+3.60%

ADILAdial Pharmaceuticals, Inc.

ADILAdial Pharmaceuticals, Inc.$2.48-0.40%

BCLIBrainstorm Cell Therapeutics Inc.

BCLIBrainstorm Cell Therapeutics Inc.$0.99+5.52%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

WENWendy's

WENWendy's$8.71+0.11%

FCUVFocus Universal

FCUVFocus Universal$5.95+0.35%

TECHBio-Techne

TECHBio-Techne$70.17+0.19%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.00-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.59+0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.56+0.02%

MARAMara Holdings

MARAMara Holdings$14.59+0.04%

Questions About MTNB

What is the current price of Matinas BioPharma?

Matinas BioPharma is trading at $0.66 per share.

What is the 52-week range for Matinas BioPharma?

Over the past 52 weeks, Matinas BioPharma has traded between $0.48 and $3.09.

How much debt does Matinas BioPharma have?

As of the most recent reporting period, Matinas BioPharma reported total debt of $1.19M.

How much cash does Matinas BioPharma have on hand?

Matinas BioPharma reported $2.45M in cash and cash equivalents in its most recent financial results.

What is Matinas BioPharma’s dividend yield?

Matinas BioPharma does not currently have a dividend yield.

Matinas BioPharma

Matinas BioPharma Financials at a Glance

MTNB News

Why Matinas BioPharma Stock Crashed Today

Why Matinas BioPharma Holdings Shot Almost 28% Higher Today

Here's Why Matinas Biopharma Shares Fell as Much as 23.6% Today

Here's Why Matinas BioPharma Shares Lost as Much as 16.9% Today

Why Matinas BioPharma Tumbled 13.4% Today

Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Matinas BioPharma

MTNB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Matinas BioPharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MTNB

What is the current price of Matinas BioPharma?

What is the 52-week range for Matinas BioPharma?

How much debt does Matinas BioPharma have?

How much cash does Matinas BioPharma have on hand?

What is Matinas BioPharma’s dividend yield?

Premium Investing Services